

\$154.58 - \$0.35 (-0.23%) as of Friday's close

52-wk Range

\$140.68  \$169.99

Cap (\$M USD)
\$371,930

P/E
17.2

EPS (1Y)
33.6%

Dividend
\$5.20

Last Filing
03/31/25

Sales (\$M)
89,331

Fwd. P/E
13.9

Sales (1Y)
4.3%

Fwd. Yield
3.4%

Next Earnings
07/16/25

Dividend Adjusted Return Apr 25, 2024 - Apr 25, 2025

JNJ 154.58 (+7.4%) Healthcare 251.47 (-0.8%) S&P 500 5525.21 (+10.3%)



JNJ has underperformed the S&P 500 by -2.9% in the past year.

JNJ has outperformed its sector by 8.2% in the past year.






The Healthcare sector has underperformed the market by -11.1% in the past year.

ANALYST CONSENSUS

Buy

The consensus rating has improved a little since last month when it was also Buy.





Strong Buy  9
Buy  2
Hold  11
Sell  0
Strong Sell  0

QUANTITATIVE SCORES

Fair Value \$163.42

Margin of Safety 6%

The Margin of Safety is the difference between a company's Fair Value and the current price. See more on page 8.

 **1 warning** 
Details on Page 8

Value Score

79

Value Score: Our value score looks at EV/EBITDA, P/E, P/S, P/TB (Price/Tangible Book) and EPS Predictability. P/S and P/TB are compared within a sector. Other metrics are compared across all stocks

Quality Score

96

Quality Score: Our quality score compares profitability and balance sheet metrics to find high quality companies using ROIC, Net Margin, Gross Margin, Interest Coverage, and Debt / Equity metrics.

Growth Score

76

Growth Score: Our growth score looks at the 5 year history and the forward estimates for EBITDA, Sales, and EPS growth, ranking the best companies across all stocks.

Sentiment Score

73

Sentiment Score: Our sentiment score finds stocks in favor by analyzing Short Interest, returns in key periods over the last year, Price vs. 52-wk High, Days Since 52-wk High and MACD signals.

BUSINESS SUMMARY

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.


Employees 139,800

Homepage www.jnj.com


Headquarters New Brunswick, NJ

VALUATION SUMMARY

	JNJ	Industry	S&P 500
Value Score	79	67	70
Price / Earnings	17.2	26.2	26.4
Price / Sales	4.2	4.2	2.9
Price / Free Cash Flow	20.2	21.4	31.6
Price / Book	4.8	5.6	4.9
Price / Tangible Book	-	-	500+
EV / EBITDA	11.1	21.6	20.8
EPS Predict. Pctl.	71	72	70
Piotroski F Score	5	6	7
5-Year P/E Range	15.8		36.6
5-Year P/B Range	4.4		7.2
5-Year P/S Range	3.9		5.7


GROWTH SUMMARY


	JNJ	Industry	S&P 500
Growth Score	76	74	77
Sales Growth			
Sales Growth Next Year	3.8%	8.1%	9.9%
Sales 1-Year Chg (%)	4.3%	8.9%	12.3%
Sales 3-Year Avg (%)	-2.0%	-2.1%	7.8%
Sales 5-Year Avg (%)	1.5%	2.8%	11.4%
EPS Growth			
Next Yr. Growth Est.	4.6%	19.2%	14.3%
EPS 1-Year Chg (%)	33.6%	48.4%	12.2%
EPS 3-Year Avg (%)	6.6%	0.1%	8.6%
EPS 5-Year Avg (%)	7.0%	2.3%	13.3%


PEERS ANALYSIS SUMMARY

Ticker	Company	Cap (\$M USD)	P/E	Fwd. Yield	1M Return	1Y Return	Margin of Safety	Value Score	Growth Score	Quality Score
LLY	Eli Lilly	\$794,307	75.8	0.7%	3.8%	22.8%	-21%	55	99	96
JNJ	Johnson & Johnson	\$371,930	17.2	3.4%	-4.0%	8.7%	6%	79	76	96
ABBV	AbbVie	\$329,136	78.1	3.5%	-6.7%	15.3%	8%	65	81	74
NVS	Novartis	\$220,832	19.1	3.6%	1.6%	17.3%	2%	82	77	96
AZN	AstraZeneca	\$216,484	31.0	2.2%	-4.8%	-5.4%	11%	63	95	92
MRK	Merck & Co	\$208,206	12.0	3.9%	-5.8%	-34.8%	29%	84	92	97
AMGN	Amgen	\$150,868	37.2	3.4%	-8.5%	7.4%	29%	78	88	77
PFE	Pfizer	\$129,989	16.3	7.5%	-10.3%	-3.6%	40%	82	61	81
GILD	Gilead Sciences	\$128,615	21.7	3.1%	-4.4%	64.0%	8%	75	76	61
SNY	Sanofi	\$126,292	18.5	4.2%	-5.6%	10.5%	23%	84	91	88
BMJ	Bristol-Myers Squibb	\$97,465	17.9	5.2%	-18.2%	12.4%	44%	85	62	83
BIIB	Biogen	\$17,395	10.6	-	-14.6%	-41.3%	46%	95	59	91

PROFITABILITY SUMMARY

	JNJ	Industry	S&P 500
Quality Score	96	78	78
Gross Margin	68.3%	72.1%	31.5%
Operating Margin	24.8%	23.9%	15.1%
Net Margin	24.4%	15.3%	11.1%
Return on Assets	12.2%	9.3%	10.5%
Return on Equity	27.9%	30.8%	33.9%
ROIC	17.4%	18.9%	24.9%



RETURNS SUMMARY

	JNJ	Industry	S&P 500
Sentiment Score	73	57	67
5-Day Return	-1.8%	4.0%	4.6%
1-Month Return	-4.0%	-3.1%	-4.4%
YTD Return	7.7%	5.2%	-5.8%
1-Year Return	8.7%	3.0%	10.8%
3-Year Return	-9.2%	15.7%	34.4%
5-Year Return	14.9%	42.1%	109.5%
Beta 1-Year	-0.02	0.35	1.00

Dividend Adjusted Return Apr 25, 2024 - Apr 25, 2025

JNJ 154.90 (+7.3%)




DIVIDEND

	JNJ	Industry
Forward Dividend Yield	3.4%	2.8%
Payout Ratio	54.8%	68.2%
TTM Yield	3.2%	-
Fwd. Div. Per Share	\$5.20	\$4.24
Div. 1Y Chg (%)	4.2%	9.5%
Div. 3Y Avg (%)	5.4%	5.4%
Div. 5Y Avg (%)	5.5%	6.0%
Cons. Growth Years	10+	4
Div. Coverage Ratio	1.7	1.4

DEBT & EQUITY

Current Ratio	1.3
Quick Ratio	1.0
Price	\$154.58
Net Cash Per Share	-\$5.73
Equity Per Share	\$32.46
Debt / Equity	0.7
Solvency Ratio	31%
Interest Coverage	34.1
Short % of Float	0.8%
Altman Z-Score	2.9

Debt / Equity 0.7

ANALYST REVISIONS

Current Quarter EPS		Next Quarter EPS	
# Up Last 30 days	2.00	# Up Last 30 days	4.00
# Down Last 30 days	12.00	# Down Last 30 days	7.00
Mean Estimate	2.68	Mean Estimate	2.69
% Change (30 Days)	-1.54%	% Change (30 Days)	-0.99%

MEAN ESTIMATE TREND

	Cur Qtr	Next Qtr	Cur Year	Next Year
Latest	\$2.68	\$2.69	\$10.62	\$11.11
30 Days Ago	\$2.72	\$2.71	\$10.57	\$11.12
90 Days Ago	\$2.70	\$2.65	\$10.50	\$11.13
% Change (90 Days)	-0.6%	1.4%	1.2%	-0.2%

EARNINGS SURPRISES

Earnings surprise is the difference between a company's announced earnings and the average analyst estimated value. Surprises typically causes the stock price to jump and are often followed by more of the same surprise type.

Surprise Summary (Last 12 Quarters)

Surprise Type	Amount	Percent
Positive Quarters (> 2%)	9	75.0%
Negative Quarters (< 2%)	0	-
In-Line Quarters (within 2%)	3	25.0%


Surprise Detail (Last 6 Quarters)

Surprise Type	Announce Date	Period End Date	Actual EPS	Est. EPS	Surprise (%)
Positive	04/15/25	03/31/25	\$2.77	\$2.59	6.9%
In-Line	01/22/25	12/31/24	\$2.04	\$2.01	1.5%
Positive	10/15/24	09/30/24	\$2.42	\$2.21	9.5%
Positive	07/17/24	06/30/24	\$2.82	\$2.70	4.4%
Positive	04/16/24	-	\$2.50	\$2.43	2.9%
In-Line	01/23/24	-	\$2.29	\$2.28	0.4%

RISK


	JNJ	Industry	S&P 500
Best Monthly Return (5Y)	16.5%	11.1%	17.9%
Worst Monthly Return (5Y)	-8.4%	-8.0%	-9.6%
Beta 1-Year	-0.02	0.35	1.00
Volatility 1-Year	0.19	0.16	0.19
Volatility 1Y Pctl.	16	-	-
Max Drawdown 1-Year	-14.4%	-27.6%	-18.7%
Max Drawdown 3-Year	-18.4%	-32.4%	-18.7%
Max Drawdown 5-Year	-18.4%	-33.9%	-24.6%

JNJ Volatility 1-Year 0.2



SEASONALITY

Seasonal Performance vs the S&P 500



5-YEAR RELATIVE PERFORMANCE VS S&P 500

Relative to the S&P 500 baseline, JNJ has underperformed the S&P 500 by -98.1% in the past 5 Years.

JNJ has underperformed its sector by -30.1% in the past 5 Years.

The Healthcare sector has underperformed the market by -68.0% in the past 5 Years.

Dividend Adjusted Return Apr 24, 2020 - Apr 25, 2025



Overall Rating
vs. Peers

93

Ratings scores are relative to industry groups. They compare key metrics to rank stocks vs. their competitors.
For example, higher growth than peers will score high even when the absolute growth is below the market average.

Growth vs Peers

Ticker	Company	Growth Rating vs. Peer	Sales QoQ Chg.	Eps QoQ Chg.	Sales Growth Next Y.	Sales 1Y Chg (%)	Sales 3Y Avg (%)	Sales 5Y Avg (%)
AZN	AstraZeneca	88	23.8%	54.8%	6.1%	13.6%	9.2%	16.4%
MRK	Merck & Co	86	6.8%	-	6.1%	4.5%	5.9%	5.9%
NVS	Novartis	83	15.1%	11.0%	1.9%	8.4%	-0.8%	0.7%
JNJ	Johnson & Johnson	60	2.4%	238.8%	3.8%	4.3%	-2.0%	1.5%
ABBV	AbbVie	50	5.6%	-	8.0%	3.5%	-0.2%	10.6%

Valuation vs Peers

Ticker	Company	Valuation Rating vs. Peer	P/E	Fwd. P/E	PEG Trailing	P/S	P/B	5Y P/E Range
MRK	Merck & Co	87	12.0	8.5	1.1	3.3	4.5	11.1 147.0
AZN	AstraZeneca	62	31.0	13.8	1.0	4.0	5.3	28.9 -
NVS	Novartis	61	19.1	12.5	1.5	4.4	5.0	7.0 33.1
JNJ	Johnson & Johnson	58	17.2	13.9	2.5	4.2	4.8	15.8 36.6
ABBV	AbbVie	8	78.1	13.4	-	5.9	99.0	15.2 91.0

Efficiency vs Peers

Ticker	Company	Efficiency Rating vs. Peer	Gross Margin	Operating Margin	Net Margin	5Y ROE Range	5Y ROA Range
MRK	Merck & Co	99	76.3%	31.5%	26.7%	1.0% 39.5%	0.3% 16.7%
JNJ	Johnson & Johnson	97	68.3%	24.8%	24.4%	17.4% 55.0%	7.0% 21.5%
NVS	Novartis	93	75.2%	28.1%	23.1%	11.7% 40.6%	5.6% 19.3%
ABBV	AbbVie	79	70.0%	21.1%	7.6%	34.8% 127.5%	3.1% 9.2%
AZN	AstraZeneca	78	81.1%	19.0%	13.0%	-3.5% 27.6%	-1.3% 6.9%

Financial Strength vs Peers

Ticker	Company	Financial Str. Rating vs. Peers	Debt / Equity	Interest Coverage	Quick Ratio	Intangibles %	Solvency Ratio	Short % of Float
MRK	Merck & Co	80	0.8	16.7	1.2	32.5%	34%	1.5%
JNJ	Johnson & Johnson	74	0.7	34.1	1.0	41.9%	31%	0.8%
AZN	AstraZeneca	71	0.7	6.2	0.7	55.9%	22%	0.3%
NVS	Novartis	70	0.7	14.6	0.8	50.5%	35%	0.2%
ABBV	AbbVie	60	20.2	2.3	0.6	70.3%	13%	1.0%


Dividends vs Peers

Ticker	Company	Dividends Rating vs. Peer	Fwd. Yield	TTM Yield	Price	Fwd. Div. Per Share	Consecutive Div. Growth Years	Payout Ratio
JNJ	Johnson & Johnson	83	3.4%	3.2%	\$154.58	\$5.20	10+	54.8%
NVS	Novartis	73	3.6%	3.6%	\$112.14	\$3.99	5	63.2%
MRK	Merck & Co	70	3.9%	3.8%	\$82.74	\$3.24	10+	46.2%
ABBV	AbbVie	58	3.5%	3.4%	\$186.06	\$6.56	10+	258.3%
AZN	AstraZeneca	55	2.2%	2.2%	\$69.57	\$1.55	1	65.4%

Momentum vs Peers

Ticker	Company	Momentum Rating vs. Peer	1M Return	3M Return	6M Return	YTD Return	1Y Return	Beta 1Y	Volatility 1Y	Price vs 52-wk High (%)
NVS	Novartis	84	1.6%	16.3%	2.1%	19.4%	17.3%	0.21	0.19	92.7%
ABBV	AbbVie	73	-6.7%	10.3%	0.9%	6.7%	15.3%	0.34	0.27	85.1%
JNJ	Johnson & Johnson	70	-4.0%	6.1%	-2.4%	7.7%	8.7%	-0.02	0.19	90.9%
AZN	AstraZeneca	57	-4.8%	2.2%	-6.0%	7.7%	-5.4%	0.34	0.22	79.4%
MRK	Merck & Co	33	-5.8%	-12.7%	-19.1%	-16.1%	-34.8%	0.26	0.26	61.5%

DIVIDEND DETAIL



CALENDAR YEAR DIVIDEND HISTORY

Year	Ex-Dividend	Pay Date	Text	Amount
2025 Dividends				\$2.54
	05/27/25	06/10/25	Regular	\$1.30
	02/18/25	03/04/25	Regular	\$1.24
2024 Dividends				\$4.91
	11/26/24	12/10/24	Regular	\$1.24
	08/27/24	09/10/24	Regular	\$1.24
	05/20/24	06/04/24	Regular	\$1.24
	02/16/24	03/05/24	Regular	\$1.19
2023 Dividends				\$4.70
	11/20/23	12/05/23	Regular	\$1.19
	08/25/23	09/07/23	Regular	\$1.19
	05/22/23	06/06/23	Regular	\$1.19
	02/17/23	03/07/23	Regular	\$1.13
2022 Dividends				\$4.45
	11/21/22	12/06/22	Regular	\$1.13
	08/22/22	09/06/22	Regular	\$1.13
	05/23/22	06/07/22	Regular	\$1.13
	02/18/22	03/08/22	Regular	\$1.06
2021 Dividends				\$4.19
	11/22/21	12/07/21	Regular	\$1.06
	08/23/21	09/07/21	Regular	\$1.06
	05/24/21	06/08/21	Regular	\$1.06
	02/22/21	03/09/21	Regular	\$1.01
2020 Dividends				\$3.98

UPCOMING DIVIDEND

Ex-Dividend Date	05/27/25
Payment Date	06/10/25
Amount	\$1.30
Type	Regular

DIVIDEND RATE

Regular Dividend	\$1.30
Forward Dividend Rate	\$5.20
Forward Dividend Yield	3.4%
Trailing 12 Months Dividends	\$4.96
Trailing 12 Months Yield	3.2%

STATISTICS

Payout Ratio	54.7
Dividend Coverage Ratio	1.7
Consecutive Growth Years	10+
3 Year Growth Rate	5.4%
5 Year Growth Rate	5.5%
10 Year Growth Rate	5.9%


FINANCIAL STATEMENT SUMMARY

USD in Millions	Chart	2020	2021	2022	2023	2024	TTM	CAGR
Income Statement								
Revenue		82,584	78,740	79,990	85,159	88,821	89,331	1.8%
Operating Income		19,733	20,943	21,013	23,409	22,149	22,175	2.7%
Net income		14,714	20,878	17,941	35,153	14,066	21,810	9.5%
Earnings per share diluted		\$5.51	\$6.66	\$6.14	\$5.20	\$5.79	\$8.99	12.0%
Average shares diluted		2,968	2,674	2,664	2,560	2,429	2,428	-4.5%
P/E Ratio		24.8	25.6	24.6	29.4	16.1	17.2	-8.1%
Balance Sheet								
Cash		25,185	31,608	22,281	22,927	24,522	38,781	10.5%
Current assets		51,237	60,979	55,294	53,495	55,893	71,551	8.0%
Net Property, Plant and Equipm...		18,766	18,962	17,982	19,898	20,518	20,871	2.5%
Working Capital		8,744	15,753	-508	7,213	5,572	14,648	12.7%
Net Debt		10,081	2,143	17,361	6,405	12,112	13,471	6.9%
Stockholders' Equity		63,278	74,023	76,804	68,774	71,490	78,109	5.0%
Cash Flow								
Operating Cash Flow		23,536	23,410	21,194	22,791	24,266	24,783	1.2%
Cap Ex		-3,347	-3,652	-4,009	-5,013	-6,207	-6,209	15.4%
Free Cash Flow		20,189	19,758	17,185	17,778	18,059	18,574	-1.9%
Free Cash Flow per share		\$6.80	\$7.39	\$6.45	\$6.94	\$7.43	\$7.65	2.8%
Profitability								
Operating Margin		23.9%	26.6%	26.3%	27.5%	24.9%	24.8%	0.9%
Return on Assets		8.8%	11.7%	9.7%	19.8%	8.1%	12.2%	7.8%
Return on Equity		23.3%	28.2%	23.4%	51.1%	19.7%	27.9%	4.3%
Return on Invested Capital		15.9%	20.4%	15.8%	32.4%	13.2%	17.3%	2.0%
Dividends								
Dividends Per Share		\$3.98	\$4.19	\$4.45	\$4.70	\$4.91	\$5.20	6.4%
Dividend Yield		2.6%	2.5%	2.6%	3.0%	3.6%	3.4%	6.4%
Dividend Growth		-	5.3%	6.2%	5.6%	4.5%	9.2%	18.4%
Dividend Coverage		1.4x	1.9x	1.5x	3.0x	1.2x	1.8x	6.3%

VALUATION & PROFITABILITY HISTORY

Date →		TTM	1 Yr Ago	2 Yrs. Ago	3 Yrs. Ago	4 Yrs. Ago
Price / Earnings		17.2	19.3	24.6	23.8	30.1
Price / Cash Flow		15.2	16.2	20.8	21.3	18.8
Price / Book		4.8	5.1	5.6	6.6	6.9
Price / Tangible B...		-	-	-	-	-
Price / Sales		4.2	4.3	4.6	5.3	5.4
EV / EBITDA		11.1	13.2	21.0	18.8	19.9
Forward Dividend...		3.4%	3.4%	2.9%	2.3%	2.4%
Shareholder Yield		4.2%	3.0%	4.6%	3.0%	3.1%
Gross Margin		68.3%	69.2%	66.9%	68.0%	66.2%
Net Margin		24.4%	44.9%	13.2%	20.9%	18.0%
Return on Assets		12.2%	21.4%	7.0%	11.2%	9.2%
Return on Equity		27.9%	55.0%	18.0%	26.5%	23.0%
ROIC		17.4%	37.8%	10.7%	18.5%	15.4%

WARNINGS

Name	Severity	Details
Downward EPS Revisions	Low 	Net EPS Rev. Cur. Qtr.: -10

Analyst estimates for the next quarter have been revised down. Check for recent news stories about why the future outlook is darker.

REPORT TIPS

Metric Definitions

Metric descriptions are available at stockrover.com/help/metrics/metric-overview

Quantitative Scores

Our scores analytics is to offer our concise analysis of a stock in powerful, but easy to digest format. Each of the composite score metrics are designed to use the best available accounting practices as well as source data from SEC filings. The scores are computed for a company vs. the market as a whole.

Fair Value

Fair value performs a forecasted discounted cash flow analysis of a company to determine the company's intrinsic value based on the expected future cash flows the company will produce. It basically determines what a company is worth based on how much cash flow it is expected to generate for you in the future, taking into account the time value of money and the predictability of those forecasted cash flows.

Peers

Peer ratings are computed from ranking companies in the same

DISCLAIMER

Financial Statements and Historical Prices Provided by Morningstar. © 2025 Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Stock Rover and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely.

The information provided does not constitute investment advice, nor does it constitute a recommendation to buy or sell any security. Stock Rover LLC and its content providers are not responsible for any losses resulting from trading decisions arising from any use of this information. Past performance is no guarantee of future results.

The information provided is as of the date written and is subject to change without notice

Additional data provided by [Zacks](#), [Intrinio](#), [Quandl](#), [Yodlee](#), [IEX Cloud](#)